About
About the collaboration
An epidemiologist at the Harvard School of Public Health and a pathologist at Dana Farber Cancer Institute came to the conclusion that the important scientific questions relating to prostate cancer could not be found in either the molecular pathology lab or in epidemiology population studies alone. To address this shortcoming, in 2008 they created the novel team now known as ToPCaP (Transdisciplinary Prostate Cancer Partnership), which integrates molecular pathology and large-scale epidemiological studies. This combined effort allows ToPCaP to effectively address the pressing prostate cancer questions of the day. This forward-thinking synergistic pairing of pathology and epidemiology provides opportunities for translational research - research that can be generated in a lab and applied in the clinic. Since its inception in 2008, ToPCaP has grown into an international consortium of researchers from diverse cross-functional fields, including epidemiology, molecular pathology, clinical oncology, genetics, biostatistics, and basic science. ToPCaP's goal is to decrease the morbidity and mortality of prostate cancer patients through groundbreaking research.
About the steering committee
The steering committee is made up of one researcher from each institution, and helps to lead the scientific agenda and priorities for the group.
 |
Ove Andrén Associate Professor of Urology Örebro University |
 |
Stephen Finn Associate Professor of Pathology Trinity College, Dublin |
 |
Michelangelo Fiorentino Lead Pathologist S. Orsola-Malpighi Hospital |
 |
Mieke Van Hemelrijck Senior Lecturer in Cancer Epidemiology King's Health Partners |
 |
Massimo Loda Professor of Pathology Dana Farber Cancer Institute |
 |
Lorelei Mucci Associate Professor of Epidemiology Harvard T.H. Chan School of Public Health |
 |
Unnur Valdimarsdóttir Professor of Epidemiology University of Iceland |